Calliditas Therapeutics AB (publ)

BATS-CHIXE:CALTXS Stock Report

Market Cap: SEK 11.2b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Calliditas Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

BATS-CHIXE:CALTXS Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
02 Sep 24SellSEK 11,826,880Elmar SchneeIndividual56,860SEK 208.00
02 Sep 24SellSEK 2,080,000Henrik StenqvistIndividual10,000SEK 208.00
02 Sep 24SellSEK 3,380,000Fredrik JohanssonIndividual16,250SEK 208.00
02 Sep 24SellSEK 152,903,298Renee Aguiar-LucanderIndividual735,112SEK 208.00
04 Jul 24SellSEK 13,885,234Fredrik JohanssonIndividual67,439SEK 206.00
03 Jul 24SellSEK 5,358,844Frank BringstrupIndividual26,319SEK 205.80
01 Jul 24SellSEK 10,458,016Richard PhilipsonIndividual50,885SEK 205.56
04 Jun 24BuySEK 1,105,603,625Asahi Kasei CorporationCompany5,367,206SEK 208.65

Insider Trading Volume

Insider Buying: CALTXS insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of CALTXS?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders91,8840.136%
VC/PE Firms2,851,7584.22%
Institutions14,186,04021%
Public Companies50,412,89774.6%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 128.25% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
93.3%
Asahi Kasei Corporation
50,412,897SEK 10.4b936%no data
5.28%
Industrifonden
2,851,758SEK 590.3m0.63%86.16%
4.2%
Polar Capital Holdings Plc
2,268,444SEK 469.6m7.27%0.17%
3.22%
Avanza Fonder AB
1,738,975SEK 360.0m0%0.42%
3.03%
Sofinnova Partners SAS
1,636,520SEK 338.8m29.2%20.95%
3.03%
Fourth Swedish National Pension Fund (AP4)
1,636,520SEK 338.8m3.71%0.13%
2.78%
BVF Partners L.P.
1,500,000SEK 310.5m-79.1%0.77%
2.69%
Unionen, Endowment Arm
1,452,884SEK 300.7m-24.8%8.68%
2.25%
E. Öhman J:or Wealth Management
1,215,238SEK 251.6m1.53%0.15%
2.01%
Handelsbanken Asset Management
1,085,612SEK 224.7m-31.4%0.03%
1.78%
The Invus Group, LLC
960,730SEK 198.9m0%60.94%
0.97%
AXA Investment Managers S.A.
526,619SEK 109.0m0%0.02%
0.69%
SEB Investment Management AB
373,402SEK 77.3m0%0.01%
0.63%
Atlant Fonder AB
339,060SEK 70.2m0%26.7%
0.62%
DNB Asset Management AS
336,007SEK 69.6m0%0.02%
0.43%
Deka Investment GmbH
231,000SEK 47.8m0%no data
0.36%
Andra AP-fonden
192,230SEK 39.8m0%0.02%
0.22%
Arctic Asset Management AS
121,121SEK 25.1m0%0.17%
0.22%
Storebrand Fonder AB,
118,776SEK 24.6m15.9%0.01%
0.13%
Aramea Asset Management AG
70,000SEK 14.5m-55.7%0.23%
0.098%
Hilde Steineger
53,199SEK 11.0m0%no data
0.095%
Ironwood Investment Management, LLC
51,254SEK 10.6m0.45%0.52%
0.083%
Optiver US LLC, Asset Management Arm
44,672SEK 9.2m781%0.02%
0.076%
Tcax Förvaltning Ab
40,898SEK 8.5m0.77%0.01%
0.074%
UBS Asset Management AG
39,911SEK 8.3m63.3%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/10/12 02:55
End of Day Share Price 2024/09/10 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Calliditas Therapeutics AB (publ) is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ingird GafanhãoBryan Garnier & Co
Alexandru CogutBryan Garnier & Co
Erik HultgårdCarnegie Investment Bank AB